Cargando…

Heterogenous and Low Expression of HER2 in Breast Cancer Overcome by DS-8201a in a Heavily Treated Patient: Case Report and Review of the Literature

Breast cancer is highly heterogenous with temporal and spatial heterogeneity making it necessary for rebiopsy. DS-8201a, a new potential therapy for human epidermal growth factor receptor 2 (HER2) low expression breast cancer, had been proved that it could overcome heterogenous HER2 expression in a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Cheukfai, Ren, Chongyang, Wen, Lingzhu, Chen, Xiaoqing, Chen, Bo, Zhang, Guochun, Wang, Yulei, Li, Kai, Cao, Li, Jia, Minghan, Mok, Hsiaopei, Lai, Jianguo, Xiao, Weikai, Li, Xuerui, Liao, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883389/ https://www.ncbi.nlm.nih.gov/pubmed/35237089 http://dx.doi.org/10.1177/11795549211072880

Ejemplares similares

Spectrum of MAP3K1 mutations in breast cancer is luminal subtype-predominant and related to prognosis
por: Li, Cheukfai, et al.
Publicado: (2022)

Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients
por: Wen, Lingzhu, et al.
Publicado: (2021)

PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing
por: Jia, Minghan, et al.
Publicado: (2021)

Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
por: Li, Kai, et al.
Publicado: (2020)

Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours
por: Chen, Bo, et al.
Publicado: (2021)

Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status
por: Zhang, Guochun, et al.
Publicado: (2022)

Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer
por: Chen, Bo, et al.
Publicado: (2020)

Genomic alteration profile and PD‐L1 expression among different breast cancer subtypes in Chinese population and their correlations
por: Li, Kai, et al.
Publicado: (2022)

Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
por: Azar, Ibrahim, et al.
Publicado: (2021)

Molecular characterization of breast cancer: a potential novel immune-related lncRNAs signature
por: Lai, Jianguo, et al.
Publicado: (2020)

EXM 82.01
por: Bariband, G
Publicado: (1982)

Identification of a novel microRNA recurrence-related signature and risk stratification system in breast cancer
por: Lai, Jianguo, et al.
Publicado: (2019)

Association of Body Mass Index With Somatic Mutations in Breast Cancer
por: Chen, Bo, et al.
Publicado: (2021)

Comprehensive analysis of autophagy‐related prognostic genes in breast cancer
por: Lai, Jianguo, et al.
Publicado: (2020)

Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer
por: Xiao, Weikai, et al.
Publicado: (2021)

Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics
por: Xiao, Weikai, et al.
Publicado: (2021)

[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti–CTLA-4 antibody in a mouse model
por: Iwata, Tomomi Nakayama, et al.
Publicado: (2019)

Stomatitis And Everolimus: A Review Of Current Literature On 8,201 Patients
por: Arena, Claudia, et al.
Publicado: (2019)

Prevalence of ESR1 Mutation in Chinese ER-Positive Breast Cancer
por: Zhu, Wenzhen, et al.
Publicado: (2020)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
por: Ogitani, Yusuke, et al.
Publicado: (2016)

Analysis of Prognostic Factors Affecting the Brain Metastases Free Survival and Survival After Brain Metastases in Breast Cancer
por: Xiao, Weikai, et al.
Publicado: (2020)

Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo
por: Zhang, Yuchen, et al.
Publicado: (2022)

GSTM1 polymorphism in Oncotype DX assay is a potential predictive factor for taxane-based neoadjuvant chemotherapy in estrogen receptor-positive Chinese breast cancer patients
por: Zhang, Guochun, et al.
Publicado: (2019)

CDKN1C as a prognostic biomarker correlated with immune infiltrates and therapeutic responses in breast cancer patients
por: Lai, Jianguo, et al.
Publicado: (2021)

Generation of a monoclonal antibody recognizing the heavily glycosylated CD45 protein and its application on identifying circulating tumor cells
por: Zhang, Weikai, et al.
Publicado: (2018)

Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions: A Case Report
por: Shan, Jianzhen, et al.
Publicado: (2020)

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
por: Zhang, Mengqi, et al.
Publicado: (2022)

Breast cancer adaptive resistance: HER2 and cancer stem cell repopulation in a heterogeneous tumor society
por: Duru, Nadire, et al.
Publicado: (2013)

Selenium-binding protein 1 transcriptionally activates p21 expression via p53-independent mechanism and its frequent reduction associates with poor prognosis in bladder cancer
por: Wang, Yulei, et al.
Publicado: (2020)

Determinants of community structure of zooplankton in heavily polluted river ecosystems
por: Xiong, Wei, et al.
Publicado: (2016)

Heavily doped semiconductors
por: Fistul’, Victor I
Publicado: (1995)

Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer
por: Lee, Kyoungmin, et al.
Publicado: (2023)

Clinicopathologic and Genomic Features in Triple-Negative Breast Cancer Between Special and No-Special Morphologic Pattern
por: Li, Ying-Zi, et al.
Publicado: (2022)

Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review
por: Qi, Xiangjun, et al.
Publicado: (2022)

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial
por: Li, Ting, et al.
Publicado: (2015)

Function of HNRNPC in breast cancer cells by controlling the dsRNA‐induced interferon response
por: Wu, Yusheng, et al.
Publicado: (2018)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer
por: Lee, Jieun, et al.
Publicado: (2017)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r6ibrilsaflvpc0fc4de9hfrlk